The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008

Kerry Schnell, Carlos O Weiss, Todd Lee, Jerry A Krishnan, Bruce Leff, Jennifer L Wolff, Cynthia Boyd, Kerry Schnell, Carlos O Weiss, Todd Lee, Jerry A Krishnan, Bruce Leff, Jennifer L Wolff, Cynthia Boyd

Abstract

Background: Treatment of chronic diseases such as chronic obstructive pulmonary disease (COPD) is complicated by the presence of comorbidities. The objective of this analysis was to estimate the prevalence of comorbidity in COPD using nationally-representative data.

Methods: This study draws from a multi-year analytic sample of 14,828 subjects aged 45+, including 995 with COPD, from the National Health and Nutrition Examination Survey (NHANES), 1999-2008. COPD was defined by self-reported physician diagnosis of chronic bronchitis or emphysema; patients who reported a diagnosis of asthma were excluded. Using population weights, we estimated the age-and-gender-stratified prevalence of 22 comorbid conditions that may influence COPD and its treatment.

Results: Subjects 45+ with physician-diagnosed COPD were more likely than subjects without physician-diagnosed COPD to have coexisting arthritis (54.6% vs. 36.9%), depression (20.6% vs. 12.5%), osteoporosis (16.9% vs. 8.5%), cancer (16.5% vs. 9.9%), coronary heart disease (12.7% vs. 6.1%), congestive heart failure (12.1% vs. 3.9%), and stroke (8.9% vs. 4.6%). Subjects with COPD were also more likely to report mobility difficulty (55.6% vs. 32.5%), use of >4 prescription medications (51.8% vs. 32.1), dizziness/balance problems (41.1% vs. 23.8%), urinary incontinence (34.9% vs. 27.3%), memory problems (18.5% vs. 8.8%), low glomerular filtration rate (16.2% vs. 10.5%), and visual impairment (14.0% vs. 9.6%). All reported comparisons have p < 0.05.

Conclusions: Our study indicates that COPD management may need to take into account a complex spectrum of comorbidities. This work identifies which conditions are most common in a nationally-representative set of COPD patients (physician-diagnosed), a necessary step for setting research priorities and developing clinical practice guidelines that address COPD within the context of comorbidity.

Figures

Figure 1
Figure 1
Prevalence of comorbidities stratified by age and gender among subjects with physician-diagnosed COPD: Disease Domain
Figure 2
Figure 2
Prevalence of comorbidities stratified by age and gender among subjects with physician-diagnosed COPD: Clinical Factors
Figure 3
Figure 3
Prevalence of comorbidities stratified by age and gender among subjects with physician-diagnosed COPD: Health Status Factors

References

    1. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA. 2005;294(10):1255–1259.
    1. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(5 Suppl):121S–126S.
    1. Anecchino C, Rossi E, Fanizza C, De Rosa M, Tognoni G, Romero M. working group ARNO project. Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population. Int J Chron Obstruct Pulmon Dis. 2007;2(4):567–574.
    1. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and functional limitation: data from the Third National Health and Nutrition Examination. J Intern Med. 2003;254(6):540–547.
    1. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease. A case–control study in a health maintenance organization. Arch Intern Med. 2000;160(17):2653–2658.
    1. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005;128(4):2005–2011.
    1. Patil SP, Krishnan JA, Lechtzin N, Diette GB. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 2003;163(10):1180–1186.
    1. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–969.
    1. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):549–555.
    1. Gray SL, Mahoney JE, Blough DK. Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother. 2001;35(5):539–545.
    1. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294(6):716–724.
    1. Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS).: National Health and Nutrition Examination Survey. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, MD; pp. 1999–2008.
    1. Boyd CM, Leff B, Wolff J, Yu Q, Zhou J, Rand C, Weiss C. Informing Clinical Practice Guideline Development and Implementation: Prevalence of Co-existing Conditions Among Adults with Heart Disease. Journal of the American Geriatrics Society. 2011;59:797–805.
    1. Cerner Multum Inc. Multum Lexicon Drug Database
    1. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA. Cardiovascular Health Study Collaborative Research Group: Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–M156.
    1. Bandeen-Roche K, Xue QL, Ferrucci L, Walston J, Guralnik JM, Chaves P, Zeger SL, Fried LP. Phenotype of frailty: characterization in the women's health and aging studies. J Gerontol A Biol Sci Med Sci. 2006;61(3):262–266.
    1. Wilhelm-Leen ER, Hall YN, Tamura MK, Chertow GM. Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey. Am J Med. 2009;122(7):664–671. e2.
    1. Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS).: National Health and Nutrition Examination Survey Analytic and Reporting Guidelines. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, MD; 2006.
    1. Dunn OJ. Multiple Comparisons Among Means. Journal of the American Statistical Association. 1961;56:52–64.
    1. van Manen JG, Bindels PJ, IJzermans CJ, van der Zee JS, Bottema BJ, Schade E. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol. 2001;54(3):287–293.
    1. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128(4):2099–2107.
    1. Sidney S, Sorel M, Quesenberry CP, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005;128(4):2068–2075.
    1. Walsh JW, Thomashow BM. COPD and co-morbidities: results of COPD Foundation national survey. ATS 2006 San Diego International Conference, San Diego, CA; 2006. pp. 19–24.
    1. Barr RG, Celli BR, Mannino DM, Petty T, Rennard SI, Sciurba FC, Stoller JK, Thomashow BM, Turino GM. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med. 2009;122(4):348–355.
    1. Yeo J, Karimova G, Bansal S. Co-morbidity in older patients with COPD–its impact on health service utilisation and quality of life, a community study. Age Ageing. 2006;35(1):33–37.
    1. Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar MC, Plaza V, Prieto L, Anto JM. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med. 1997;127(12):1072–1079.
    1. van Manen JG, Bindels PJ, Dekker EW, Ijzermans CJ, Bottema BJ, van der Zee JS, Schade E. Added value of co-morbidity in predicting health-related quality of life in COPD patients. Respir Med. 2001;95(6):496–504.
    1. Oostenbrink JB, Rutten-van Molken MP. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med. 2004;98(9):883–891.
    1. Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J. Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature. COPD. 2006;3(4):211–218.
    1. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J. 2006;28(6):1245–1257.
    1. Frogale K, Schnell KM, Boyd CM. COPD, Comorbidity, and Disease-Specific Clinical Practice Guidelines. Edited by Nici L, ZuWallack R, New York: Humana Press; 2012. pp. 193–210.
    1. Anonymous. Can beta-blockers be used for people with COPD? Drug Ther Bull. 2011;49(1):2–5.
    1. Halpin DM. Lessons from the major studies in COPD: problems and pitfalls in translating research evidence into practice. Prim Care Respir J. 2010;19(2):170–179.
    1. Herland K, Akselsen JP, Skjonsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir Med. 2005;99(1):11–19.
    1. Barnes PJ. Future treatments for chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc. 2008;5(8):857–864.
    1. Keddissi JI, Younis WG, Chbeir EA, Daher NN, Dernaika TA, Kinasewitz GT. The use of statins and lung function in current and former smokers. Chest. 2007;132(6):1764–1771.
    1. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–2560.
    1. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007;29(2):279–283.
    1. Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008;101(4):530–535.
    1. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: a systematic review. Chest. 2009;136(3):734–743.
    1. Sonetti DA, Hospenthal AC, Adams SG. Integrated management strategies for chronic obstructive pulmonary disease. J Multidiscip Healthc. 2010;3:181–188.
    1. Jassem E, Kozielski J, Gorecka D, Krakowiak P, Krajnik M, Slominski JM. Integrated care for patients with advanced chronic obstructive pulmonary disease: a new approach to organization. Pol Arch Med Wewn. 2010;120(10):423–428.
    1. Kent DM, Kitsios G. Against pragmatism: on efficacy, effectiveness and the real world. Trials. 2009;10:48.
    1. Barr RG, Herbstman J, Speizer FE, Camargo CA. Validation of self-reported chronic obstructive pulmonary disease in a cohort study of nurses. Am J Epidemiol. 2002;155(10):965–971.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅